Reading HIMS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HIMS free→
HIMS
Hims & Hers HealthNYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-12
Intact
$26.82-7.10%
Close 2026-06-12 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is neutral. Earnings quality cannot be assessed since the company is unprofitable. Management's recent track record has been unsteady, with frequent changes. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, HIMS is below typical. Peer multiples imply a price about 174% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified. Rich on today's multiple, but the three-year horizon reads cheaper once expected earnings growth is included. If HIMS cuts guidance on the next call, that could be negative. This read is provisional.
as of 2026-06-12
Quick facts
- Exchange
- NYSE
- Sector
- Health Care
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $6.68B
- Employees
- —
- IPO date
- 2019-06-28
- Next earnings
- 2026-08-10
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 5 valuation methods, at three horizons. Current price $26.82. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryexpensive
$9.78consensus
Range $9.31 – $23.09
vs price: +174% above
Method agreement — · 5 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearinexpensive
$84.30consensus
Range $84.30 – $84.30
vs price: -68% below
Method agreement — · 1 method
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Durable premiumlow confidence
At $27 the market pays 56× p/e — above the 19× p/e peer median but in line with its own 58× history. That premium reflects a durable franchise our peer-anchored $9.78 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $12–$35. Not investment advice.
Multiple (P/E)
55.9x
peer 19.4x · own history 57.6x
Premium
2.9x peer
1.0x its own history
Growth the price needs
174%
our forecast 30%
Our fair value
$9.78
range $9.31 – $19.35
Analyst range(a guide on our number, not a target)Our number is below the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
expensiveexpensive — growth-justified12-month view
What's priced inUnjustified
The market is pricing in roughly 174% near-term growth, well above our forecast of about 30%. This describes what's priced in, not a forecast of the move.
Elevated fragilityrisk posture, not a price call
Flags: expensive valuation, a turbulent sector regime (Heating).
Historical context
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
neutralOperating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
59th pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted -21.18x of net income into operating cash flow.
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
Management & capital allocation
volatile6 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bearishEPS revised -143.2% / 30d, n=1for period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $0.09 → $-0.04 (-143.2% / 30d). 0 raised, 10 cut, 1 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d, 3 maintained. 25% of analysts rate Buy.
Price target activity
3 PT revisions / 30d. Avg target -2.7% above current price.
Material events
2 positive, 3 negative / 30d. See F4 management tile for the event list.
Sector context
Intermediate · WeeklySector phase: is in (~0.5 years in phase).
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: weak
- Capital allocation
- neutral
- Earnings discipline
- weak
- Margin discipline
- weak
- Balance sheet
- weak
- Post-call reaction
- weak
A guidance track record builds as the company issues and delivers on guidance.
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$367.
How much price usually moves either way.
On a bad day, this stock has moved -$779.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,806.
Deepest peak-to-trough drop in the last year.
elevatedas of 2026-06-12
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideHigh confidenceMonthsactive 7d
Watch for Q2 2026 revenue guidance to meet or exceed $680 million
Why it matters: Meeting or exceeding this revenue range would show strong growth momentum and confidence in the business.
What confirms / what disproves
Confirms:Q2 2026 revenue reported at or above $680 million.
Disproves:Q2 2026 revenue reported below $680 million.
Earnings call
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for HIMS yet.
This sector is also watching
- Watch for Health Care revenue growth dropping below 8% YoY
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like HLN, TEVA, and ZTS keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting HIMS and other Healthcare names. Worth watching these names for early signals.
- If HIMS raises forward guidance on the next earnings call (currently NEW as of 2026-06-02), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for HIMS and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If HIMS cuts guidance on the next call (currently NEW as of 2026-06-02), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like HLN, TEVA, and ZTS start missing or guiding lower, the Healthcare tailwind helping HIMS and other Healthcare names could fade. Watch these names for early warning.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-06-0211d agoItem 1.01
Entry Into a Material Definitive Agreement On May 29, 2026, Hims & Hers Health, Inc. (the “ Company ”), as borrower, entered into Amendment No. 3 (the “ Amendment ”) to the Revolving Credit and Guaranty Agreement, dated as of February 18, 2025 (as amended by that certain Amendment No. 1 to the Revolving Credit and Guaranty Agreement, dated as of June 25, 2025, that certain Amendment No. 2 to the Revolving Credit and Guaranty Agreement, dated as of May 7, 2026, and as amended by this Amendment…
Capital allocationneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
-2.8 vs last weeklatest as of 2026-06-13
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.